远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00512 远大医药

未开盘 04-13 16:08:48

6.610

-0.250

-3.64%

最高6.860	最低6.600	成交量283.60万
今开6.860	昨收6.860	日振幅3.79%
总市值234.66亿	流通市值234.63亿	总股本35.50亿
成交额1,891万	换手率0.08%	流通股本35.50亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"远大医药","latestPrice":6.61,"timestamp":1776067728002,"preClose":6.86,"halted":0,"volume":2836000,"delay":0,"changeRate":-0.03644314868804664,"floatShares":3549571148,"shares":3550000000,"eps":0.3544,"marketStatus":"未开盘","change":-0.25,"latestTime":"04-13 16:08:48","open":6.86,"high":6.86,"low":6.6,"amount":18913387,"amplitude":0.037901,"askPrice":6.63,"askSize":45500,"bidPrice":6.61,"bidSize":209000,"shortable":3,"etf":0,"ttmEps":0.3544,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776130200000},"marketStatusCode":0,"adr":0,"listingDate":819302400000,"exchange":"SEHK","adjPreClose":6.86,"dividendRate":0.039334,"openAndCloseTimeList":[[1776043800000,1776052800000],[1776056400000,1776067200000]],"volumeRatio":0.42963779686471143,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512/tweets","defaultTab":"tweets","newsList":[{"id":"2627455205","title":"“Go Global”再结硕果！远大医药(00512)钇[90Y]微球注射液美国临床达终点数据全球领先，驱动全球自主销售放量加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2627455205","media":"智通财经","labels":["dataReport"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627455205?lang=zh_cn&edition=full","pubTime":"2026-04-13 21:16","pubTimestamp":1776086193,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，远大医药重磅核药SIR-Spheres钇[90Y]微球注射液(易甘泰)再度迎来里程碑进展！4月13日，远大医药发布公告称，公司钇[90Y]微球注射液在美国开展的用于治疗不可切除肝细胞癌临床研究已成功达到预设临床终点，取得了极为亮眼的临床数据。肝癌是全球第六大新发癌症以及第三大致死癌症。根据GLOBOCAN 2022年的数据，肝癌全球新发病例约87万，死亡病例约76万。此次钇[90Y]微球注射液成功达到海外临床","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"“Go Global”再结硕果！远大医药(00512)钇[90Y]微球注射液美国临床达终点数据全球领先，驱动全球自主销售放量加速","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625912121","title":"远大医药：与香港大学达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2625912121","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625912121?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:38","pubTimestamp":1775641120,"startTime":"0","endTime":"0","summary":"南财智讯4月8日电，远大医药（00512.HK）发布自愿公告，宣布与香港大学及其全资子公司港大科桥有限公司达成战略合作。双方将在学术研究、资源共享、人才培养及产品开发等方面深度合作，以创新抗菌药物开发为起点，由李学臣教授团队承接研发，旨在解决抗菌治疗领域未被满足的临床需求；后续香港大学将相关知识产权独家授权予远大医药，由其负责开发、注册及商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698144219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190352339","title":"远大医药3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1190352339","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190352339?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:42","pubTimestamp":1775133729,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司于2026年4月2日披露3月股份变动月报表，报告期为2026年3月。根据公告披露，本月公司注册股本维持为100,000,000,000股，面值每股0.01港元，总额为1,000,000,000港元，未出现任何增加或减少。无新增股份发行、购回或注销，也未出现库藏股变动。公告同时显示，公司符合香港联交所对于公众持股量的相关要求。董事会确认本月并无涉及购回股份或其他可能影响已发行股本的事项。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624527327","title":"远大医药增资至34.3亿元 增幅约46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624527327","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624527327?lang=zh_cn&edition=full","pubTime":"2026-04-02 12:35","pubTimestamp":1775104517,"startTime":"0","endTime":"0","summary":"每经AI快讯，天眼查工商信息显示，近日，远大医药（中国）有限公司发生工商变更，注册资本由约23.5亿元人民币增至约34.3亿元人民币，增幅约46%。该公司成立于1990年2月，法定代表人为唐纬坤，经营范围包括药品生产、药品批发、药品进出口等。股东信息显示，该公司由远大医药（香港）有限公司、武汉和勤艾管理咨询有限公司等共同持股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693176391.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693176391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623678703","title":"部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623678703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623678703?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:23","pubTimestamp":1774837415,"startTime":"0","endTime":"0","summary":"金吾财讯 | 部分创新药概念股逆市上扬，荣昌生物 涨4.99%，康方生物涨4.75%，诺诚健华涨3.66%，先声药业涨2.73%，远大医药涨2.65%，和黄医药涨1.37%。据人民日报从国家药监局获悉，今年截至目前，我国创新药对外授权交易总额超过600亿美元，接近2025年全年的一半。今年截至3月27日，我国共批准上市10款创新药，其中8款是中国原创新药。2025年，我国批准创新药76个，创历史新高；创新药对外授权交易总金额突破1300亿美元，同样创历史新高。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977637","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK1574","LU0348766576.USD","LU2778985437.USD","IE00B543WZ88.USD","00512","LU1064130708.USD","LU2476274308.USD","LU2488822045.USD","LU0540923850.HKD","LU0348767384.USD","BK1587","BK1588","IE00BPRC5H50.USD","LU0348784397.USD","LU0348783233.USD","LU1064131003.USD","LU0348827113.USD","02096","LU0417516738.SGD","LU2476274720.SGD","LU0417516902.SGD","LU0348735423.USD","IE00B5MMRT66.SGD","09995","688331","LU1720050803.USD","LU0561508036.HKD","06978","09926","BK1583","LU2399975544.HKD","LU1969619763.USD","09969","LU0417516571.SGD","LU2328871848.SGD","BK1161","LU0634319403.HKD","BK0239","LU1961090484.USD","BK1191","00013","LU0348825331.USD","LU2148510915.USD","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145460499","title":"异动解读 | 董事会主席增持提振信心，远大医药盘中大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145460499","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145460499?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:34","pubTimestamp":1774834494,"startTime":"0","endTime":"0","summary":"远大医药今日盘中大涨5.01%，引起了市场的广泛关注。消息面上，香港联交所最新资料显示，董事会主席唐纬坤于3月27日增持公司6万股，每股作价6.5港元，总金额为39万港元。增持后，其最新持股数目为106万股，持股比例为0.03%。此举被市场视为内部人士对公司未来发展充满信心的积极信号，从而推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623699393","title":"远大医药获董事会主席唐纬坤增持6万股 每股作价6.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623699393","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623699393?lang=zh_cn&edition=full","pubTime":"2026-03-30 08:11","pubTimestamp":1774829460,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，3月27日，董事会主席唐纬坤增持远大医药（00512）6万股，每股作价6.5港元，总金额为39万港元。增持后最新持股数目为106万股，最新持股比例为0.03%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-30/doc-inhsthzk6668774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622826365","title":"董事会主席唐纬坤增持远大医药(00512)6万股 每股作价6.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826365","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622826365?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:12","pubTimestamp":1774609945,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，3月27日，董事会主席唐纬坤增持远大医药(00512)6万股，每股作价6.5港元，总金额为39万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260327/20260327191250_33818.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260327/20260327191250_33818.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622182298","title":"核药领跑+创新突破：远大医药(00512)2025年价值兑现加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2622182298","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622182298?lang=zh_cn&edition=full","pubTime":"2026-03-27 08:50","pubTimestamp":1774572600,"startTime":"0","endTime":"0","summary":"智通财经APP了解到，3月26日，远大医药公布了其2025年度业绩。其中，针对前列腺癌诊断的核药TLX591-CDx于2025年在国内顺利完成III期临床研究且达到研究终点，并于2026年初进入新药上市申请阶段，有望成为公司核药板块的下一个重磅商业化产品。创新产品持续突破，多元矩阵共筑护城河在技术优势向市场优势转化的逻辑驱动下，远大医药近年来实现了持续且可验证的成长。而STC3141这一First-in-Class药物的突破，则是远大医药创新研发的又一具象化体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622862195","title":"远大医药(00512.HK)：2025年股东应占经调整经营性纯利为14.94亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622862195","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622862195?lang=zh_cn&edition=full","pubTime":"2026-03-26 23:57","pubTimestamp":1774540621,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨远大医药公布2025年年度业绩，报告期内，收益约港币122.83亿元，同比增长约5.5%，如果撇除集采降价影响，收益同比上涨约14.8%。集团产品结构转型升级取得里程碑式成效，创新和壁垒产品收入占比实现历史性突破，首次提升至约50%，同比提升了近10个百分点，充分印证了集团战略布局的前瞻性，更为长期高品质发展构筑了坚实的核心支撑和强劲动能。董事会建议派发2025年年度末期股息每股港币0.169元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260326/32102688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622861698","title":"远大医药(00512)创新收入占比创新高!核药板块收入四年增长近十五倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2622861698","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622861698?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:56","pubTimestamp":1774537016,"startTime":"0","endTime":"0","summary":"年内，公司核药抗肿瘤诊疗板块核心产品持续放量，该板块收入取得约9.5亿港元，同比大幅增长约61%，板块四年内实现了近十五倍的增长。两款产品形成的诊疗一体化的产品布局，将进一步增厚远大医药在核药板块的竞争优势，进一步抢滩国内近500亿元规模的前列腺癌药物市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186946443","title":"远大医药将于2026年6月30日派发末期股息每股0.169港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186946443","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186946443?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:53","pubTimestamp":1774536789,"startTime":"0","endTime":"0","summary":"远大医药(00512)于2026年3月26日发布公告，宣布截至2025年12月31日止年度的末期股息为每股0.169港元，股东须于2026年6月5日批准后派发。除净日定于2026年6月12日，股东如欲符合获派息资格，需于2026年6月15日16时30分前递交股份过户文件。公司将于2026年6月16日暂停办理股份过户登记，记录日期为同日，股息派发日为2026年6月30日。\n公告显示，董事会由四名执行董事（唐纬坤博士、周超先生、林芷伊女士、杨光先生）及四名独立非执行董事（苏彩云女士、邢丽娜博士、裴更博士、胡野碧先生）组成。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622786905","title":"强劲韧性穿越周期释放长期发展价值，远大医药(00512)2025年实现收入122.8亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622786905","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622786905?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:52","pubTimestamp":1774536751,"startTime":"0","endTime":"0","summary":"智通财经APP讯，3月26日，远大医药 披露2025年财报，公司全年实现收入约122.8亿港元，剔除集采影响同比增长约14.8%，公司拥有人应占经调整经营性纯利约14.9亿港元，公司创新壁垒产品营收占总营收比例首次提升至约50%，同比大幅提升近10个百分点，标志着公司已实现创新驱动发展的深度转型。2025年，远大医药核药抗肿瘤诊疗板块实现跨越式发展，该板块收入取得约9.5亿港元，同比大幅增长约61.0%，板块收入四年增长近十五倍，持续巩固其领军地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"强劲韧性穿越周期释放长期发展价值，远大医药(00512)2025年实现收入122.8亿港元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622024791","title":"远大医药(00512)：中药1类创新药GPN01020在中国获批开展II期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024791","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622024791?lang=zh_cn&edition=full","pubTime":"2026-03-25 18:04","pubTimestamp":1774433064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 发布公告，近日，集团用于预防性治疗偏头痛的中药创新药GPN01020正式获得中华人民共和国国家药品监督管理局(药监局)批准开展II期临床研究。前期数百人的研究者发起的临床研究结果显示，GPN01020在减少偏头痛发作天数与发作频次、改善偏头痛相关症状等方面表现出良好疗效与安全性。集团的GPN01020有望为临床提供一种新的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06978","BK1191","01020","00512","BK1094","159992","BK1574","BK1142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194194361","title":"远大医药GPN01020获国家药监局批准开展偏头痛预防II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1194194361","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194194361?lang=zh_cn&edition=full","pubTime":"2026-03-25 18:03","pubTimestamp":1774433034,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司宣布，其研发的GPN01020已获得中国国家药品监督管理局（NMPA）批准，将正式进入针对偏头痛预防的II期临床试验阶段。\n这一重要进展标志着公司在该创新药物研发道路上迈出了关键一步，有望为偏头痛患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621406605","title":"远大医药(00512)核药战略伙伴Telix全球首创rADC国际多中心III期获积极进展，前列腺癌治疗添新希望！","url":"https://stock-news.laohu8.com/highlight/detail?id=2621406605","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621406605?lang=zh_cn&edition=full","pubTime":"2026-03-24 18:59","pubTimestamp":1774349976,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，远大医药核药领域战略合作伙伴澳洲Telix公司传来重磅利好，其用于治疗前列腺癌的全球首创的镥标记的治疗性放射性抗体药物偶联物候选药物TLX591-Tx国际多中心III期临床试验的第一部分已成功达到主要目标，证明了该产品的安全性和耐受性，且未观察到新的不良反应，不仅促进了该创新产品未来的进一步开发及上市，同时也体现了前列腺癌治疗未来有望获得全新选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK4134","BK0183","BK0012","BK1191","00512","BK0188","BK0187","BK0196","BK0238","III","000876"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621777227","title":"2.5亿患者福音！远大医药（00512）莱特灵®复方鼻喷重磅落地，持续领跑呼吸全周期管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777227","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621777227?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:49","pubTimestamp":1774262975,"startTime":"0","endTime":"0","summary":"莱特灵作为复方制剂，拥有现有的单方制剂无可比拟的优势。庞大的患者规模下，我国过敏性鼻炎药物市场早已突破百亿规模，且预计将持续增长。目前远大医药正积极推进莱特灵的国家创新药医保谈判准备工作，未来随着医保准入的落地，产品的临床可及性将进一步提升，覆盖更广泛的患者群体。结合国内近2.5亿的患病人群和百亿级鼻炎用药市场规模，莱特灵具备极强的市场放量潜力，有望成为鼻炎治疗领域的爆款单品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"2.5亿患者福音！远大医药（00512）莱特灵®复方鼻喷重磅落地，持续领跑呼吸全周期管理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621714302","title":"远大医药(00512)：全球创新的治疗蠕形螨睑缘炎产品TP-03在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2621714302","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621714302?lang=zh_cn&edition=full","pubTime":"2026-03-22 18:13","pubTimestamp":1774174409,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 发布公告，集团引进的用于治疗蠕形螨睑缘炎的全球创新眼科药物GPN01768 “TP-03， 0.25%”近日正式获得中国国家药品监督管理局颁发的药品注册证书，且在药品审评过程中未收到补充资料通知，实现“零发补”获批上市。GPN01768 于2023年7月获得美国食品药品监督管理局批准上市，成为全球首款也是唯一一款批准用于治疗蠕形螨睑缘炎的产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"远大医药(00512)：全球创新的治疗蠕形螨睑缘炎产品TP-03在中国获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621771915","title":"远大医药预计2025年净利润减少至12亿港元至12.5亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621771915","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621771915?lang=zh_cn&edition=full","pubTime":"2026-03-22 16:04","pubTimestamp":1774166640,"startTime":"0","endTime":"0","summary":"3月20日，远大医药（00512）发布公告，预期截至2025年12月31日止年度的本公司拥有人应占期内溢利在12亿港元至12.5亿港元之间，相比于2024年同期的24.7亿港元，预计将大幅减少。同时，预计截至2025年同期的本公司拥有人应占经调整的经营性纯利在14.5亿港元至15亿港元之间，而2024年同期为17.6亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603223679731313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620320267","title":"科技创新赋能核心竞争力，远大医药(00512)2025业绩稳健增长，创新核药继续保持高速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2620320267","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620320267?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:39","pubTimestamp":1774017590,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月20日晚，远大医药发布了2025年业绩预告，公司全年收入预计约为120亿港元至125亿港元之间，同比增长约3%至7%，创新壁垒产品收入占比实现历史性突破，首次提升至约50%；其中核药抗肿瘤诊疗板块核心产品持续放量，营收同比保持高速增长。目前，全球核药市场正处于高速扩容期。在这种革命性的治疗价值之下，STC3141显然具备不可估量的市场潜力，有望成为远大医药业绩增长的重磅引擎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科技创新赋能核心竞争力，远大医药(00512)2025业绩稳健增长，创新核药继续保持高速增长","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":-0.0845},{"period":"1month","weight":-0.0742},{"period":"3month","weight":-0.1558},{"period":"6month","weight":-0.2027},{"period":"1year","weight":0.1699},{"period":"ytd","weight":-0.158}],"compareEarnings":[{"period":"1week","weight":0.0217},{"period":"1month","weight":0.0077},{"period":"3month","weight":-0.0442},{"period":"6month","weight":-0.0096},{"period":"1year","weight":0.2269},{"period":"ytd","weight":0.0012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"远大医药集团有限公司是一家主要从事医药业务的投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械。该公司还从事制造及销售生物技术产品、健康产品、精品原料药和其他产品。该公司的主要产品包括核药抗肿瘤诊疗及心脑血管介入诊疗科技产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.451613,"avgChangeRate":0.084101},{"month":2,"riseRate":0.709677,"avgChangeRate":0.105021},{"month":3,"riseRate":0.387097,"avgChangeRate":0.015578},{"month":4,"riseRate":0.612903,"avgChangeRate":0.015809},{"month":5,"riseRate":0.466667,"avgChangeRate":0.084333},{"month":6,"riseRate":0.366667,"avgChangeRate":-0.048262},{"month":7,"riseRate":0.366667,"avgChangeRate":-0.015905},{"month":8,"riseRate":0.4,"avgChangeRate":0.007133},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.039275},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014834},{"month":11,"riseRate":0.5,"avgChangeRate":0.085694},{"month":12,"riseRate":0.5,"avgChangeRate":-0.007596}],"exchange":"SEHK","name":"远大医药","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"远大医药,00512,远大医药股票,远大医药股票老虎,远大医药股票老虎国际,远大医药行情,远大医药股票行情,远大医药股价,远大医药股市,远大医药股票价格,远大医药股票交易,远大医药股票购买,远大医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}